NCT07157514Phase 2, phase 3Not yet recruiting

Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML

Study sponsor: Actinium Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-02Estimated
Enrollment · participants306Estimated
Source updated2025-09-10Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.